Cryolife (NYSE:CRY) is scheduled to announce its earnings results after the market closes on Wednesday, March 7th. Analysts expect the company to announce earnings of $0.11 per share for the quarter.
Shares of Cryolife (NYSE CRY) opened at $19.00 on Wednesday. The company has a current ratio of 5.96, a quick ratio of 4.90 and a debt-to-equity ratio of 0.29. Cryolife has a 52-week low of $14.02 and a 52-week high of $24.00. The company has a market capitalization of $686.67, a PE ratio of 67.86 and a beta of 0.77.
A number of analysts have recently commented on CRY shares. Canaccord Genuity reiterated a “buy” rating and set a $25.00 target price on shares of Cryolife in a research report on Wednesday, January 3rd. Northland Securities reiterated a “buy” rating and set a $23.50 target price on shares of Cryolife in a research report on Monday, November 13th. Finally, Zacks Investment Research upgraded Cryolife from a “sell” rating to a “hold” rating in a research report on Tuesday, January 16th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $24.83.
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.